Comments Subscribe to Personal Liberty News Feed Subscribe to Personal Liberty

Pfizer Confirms $100 Billion Bid For AstraZeneca

LONDON, April 28 (UPI) — Pfizer has contacted AstraZeneca to buy the company in a multibillion dollar deal, the second such attempt after the latter rejected a roughly $100 billion offer in January.

News of the offer saw AstraZeneca stocks rise sharply, at the same time Pfizer’s share were up 2.7 percent around 12:30 p.m. Pfizer said it had made an initial approach in January but AstraZeneca rejected the offer saying it “significantly undervalued” the company.

Pfizer said the deal was “a highly compelling opportunity” for AstraZeneca’s shareholders. The cash and shares deal represented a 30 percent premium on AstraZeneca’s stock price in early January.

AstraZeneca said it was confident in its strategy and said it would continue to create value for its shareholders.

“The Board remains confident in the ongoing execution of AstraZeneca’s strategy as an independent company,” it added.

Pfizer, in the meantime, said that post-merger it plans to establish a new holding company in the U.K. with management both in the U.S. and U.K. The company headquarters would continue to be New York and shares would be listed on the NYSE.

AstraZeneca manufactures drugs in 16 countries focusing on treatments for diabetes, cancer and asthma as well as antibiotics.

“We have great respect for AstraZeneca and its proud heritage,” said Pfizer chairman and chief executive Ian Read.

“The strategic, business and financial rationale for a transaction is compelling,” he added.
Ananth Baliga

UPI - United Press International, Inc.

Since 1907, United Press International (UPI) has been a leading provider of critical information to media outlets, businesses, governments and researchers worldwide.

Facebook Conversations

Join the Discussion:
View Comments to “Pfizer Confirms $100 Billion Bid For AstraZeneca”

Comment Policy: We encourage an open discussion with a wide range of viewpoints, even extreme ones, but we will not tolerate racism, profanity or slanderous comments toward the author(s) or comment participants. Make your case passionately, but civilly. Please don't stoop to name calling. We use filters for spam protection. If your comment does not appear, it is likely because it violates the above policy or contains links or language typical of spam. We reserve the right to remove comments at our discretion.

Is there news related to personal liberty happening in your area? Contact us at


Sign Up For Personal Liberty Digest™!

PL Badge

Welcome to,
America's #1 Source for Libertarian News!

To join our group of freedom-loving individuals and to get alerts as well as late-breaking conservative news from Personal Liberty Digest™...

Privacy PolicyYou can opt out at any time. We protect your information like a mother hen. We will not sell or rent your email address to anyone for any reason.